How to buy AgeX Therapeutics shares | $0.795

Own AgeX Therapeutics shares in just a few minutes. Share price changes are updated daily.


Fact checked

AgeX Therapeutics, Inc (AGE) is a leading biotechnology business based in the US. It opened the day at $0.8379 after a previous close of $0.798. During the day the price has varied from a low of $0.7753 to a high of $0.87. The latest price was $0.795 (25 minute delay). AgeX Therapeutics is listed on the NYSE MKT and employs 17 staff. All prices are listed in US Dollars.

How to buy shares in AgeX Therapeutics

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: AGE in this case.
  5. Research AgeX Therapeutics shares. The platform should provide the latest information available.
  6. Buy your AgeX Therapeutics shares. It's that simple.

How has Coronavirus impacted AgeX Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, AgeX Therapeutics's share price has had significant positive movement.

Its last market close was $1.78, which is 25.84% up on its pre-crash value of $1.32 and 137.33% up on the lowest point reached during the March crash when the shares fell as low as $0.75.

If you had bought $1,000 worth of AgeX Therapeutics shares at the start of February 2020, those shares would have been worth $625.96 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,358.78.

AgeX Therapeutics share price

Use our graph to track the performance of AGE stocks over time.

AgeX Therapeutics shares at a glance

Information last updated 2020-09-29.
Previous close$0.798
Change $-0.003
Change % -0.376%
Volume 282,306
Information last updated 2020-10-21.
52-week range$0.68 - $2.59
50-day moving average $1.1227
200-day moving average $0.9893
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.318
eToro Free Stocks

Invest in AgeX Therapeutics shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Zero platform fee
Your first 50 trades are free with Fineco, until 31/12/2020. T&Cs apply.
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Capital at risk.
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
Hargreaves Lansdown Fund and Share Account
No fees
Cashback offer: Take control of your money and transfer investments to HL – get cashback as a thank you. Terms apply.
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
Interactive Investor
From £7.99 on the Investor Service Plan
From £7.99 on the Investor Service Plan
No transfer fees or exit fees. £9.99 a month on the Investor Service Plan
Open an ISA, Trading Account or SIPP you will get £100 of free trades to buy or sell any investment (new customers only).
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Moneyfarm stocks and shares ISA
Hargreaves Lansdown stocks and shares ISA
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Nutmeg stocks and shares ISA
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
Legal & General stocks and shares ISA
Legal & General stocks and shares ISA
£100 or £20 a month
Legal & General is a big financial services company which offers insurance, lifetime mortgage, pensions and stocks and shares ISAs. Capital at risk.

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Moneyfarm Pension
£1,500 (initial investment)
7 funds
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
AJ Bell Pension
Over 2,000 funds
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
Moneybox Pension
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.

Is it a good time to buy AgeX Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

AgeX Therapeutics price performance over time

Historical closes compared with the last close of $0.795

1 week (2020-10-15) -54.57%
1 month (2020-09-25) -5.36%
3 months (2020-07-24) -40.23%
6 months (2020-04-24) -7.45%
1 year (2019-10-25) -49.36%

AgeX Therapeutics financials

Revenue TTM $1.9 million
Gross profit TTM $1.5 million
Return on assets TTM -98.37%
Return on equity TTM -453.02%
Profit margin 0%
Book value $0.115
Market capitalisation $62.6 million

TTM: trailing 12 months

How to short and sell AgeX Therapeutics shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "AGE.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 1.4 million AgeX Therapeutics shares held short by investors – that's known as AgeX Therapeutics's "short interest". This figure is 0.9% down from 1.4 million last month.

There are a few different ways that this level of interest in shorting AgeX Therapeutics shares can be evaluated.

AgeX Therapeutics's "short interest ratio" (SIR)

AgeX Therapeutics's "short interest ratio" (SIR) is the quantity of AgeX Therapeutics shares currently shorted divided by the average quantity of AgeX Therapeutics shares traded daily (recently around 173190.71518193). AgeX Therapeutics's SIR currently stands at 7.97. In other words for every 100,000 AgeX Therapeutics shares traded daily on the market, roughly 7970 shares are currently held short.

However AgeX Therapeutics's short interest can also be evaluated against the total number of AgeX Therapeutics shares, or, against the total number of tradable AgeX Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AgeX Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 AgeX Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.065% of the tradable shares (for every 100,000 tradable AgeX Therapeutics shares, roughly 65 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against AgeX Therapeutics.

Find out more about how you can short AgeX Therapeutics stock.

AgeX Therapeutics share dividends

We're not expecting AgeX Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Have AgeX Therapeutics's shares ever split?

AgeX Therapeutics's shares were split on a 15:16 basis on 6 May 2015. So if you had owned 16 shares the day before before the split, the next day you'd have owned 15 shares. This wouldn't directly have changed the overall worth of your AgeX Therapeutics shares – just the quantity. However, indirectly, the new 6.7% higher share price could have impacted the market appetite for AgeX Therapeutics shares which in turn could have impacted AgeX Therapeutics's share price.

AgeX Therapeutics overview

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site